Figure 4
From: AAV9-mediated gene transfer of desmin ameliorates cardiomyopathy in desmin-deficient mice
Follow-up echocardiography. Mice were injected at the age of 2 months following baseline echocardiography. (a) Systolic left-ventricular (LV) function was significantly reduced in the AAV-LUC group (n=9) after 12 months in comparison with AAV-DES-treated knockout mice (n=10). (b) LV end-diastolic diameter in the AAV-LUC group was significantly increased when compared with WT (n=12) controls, while no significant differences were detectable between the AAV-DES group and WT controls (P=0.7). *P<0.05, ***P<0.001. † premature death of an AAV-LUC animal.
